Aurobindo Pharma Ltd. and Novartis AG have called off their 2018 deal under which the Indian firm had snapped up Sandoz International GMBH’s US generic oral solids and dermatology businesses in a transaction worth around $1bn.
The decision, both parties said, was taken as US Federal Trade Commission clearance was not obtained within anticipated timelines.





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
